Piper Sandler raised the firm’s price target on Doximity (DOCS) to $42 from $40 and keeps an Overweight rating on the shares. The firm had the opportunity to demo Doximity’s AI tool suite last week in a session hosted by CEO Jeff Tangney. DoxGPT stands out for three reasons, in Piper’s view. First for its synergistic position within the Doximity ecosystem; second for the quality and accuracy of its clinical reference responses; and finally for the evidence base supporting its medical AI.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Down Over 30% This Year: Analysts Double Down on These 3 Beaten-Down Stocks
- Doximity upgraded to Buy from Hold at Canaccord
- Doximity: Network Effects, Normalizing Pharma Budgets, and Undemanding Valuation Create an Attractive Buy Opportunity
- Doximity (DOCS) Earnings Call: AI, Buybacks and Growth
- Doximity price target lowered to $38 from $60 at KeyBanc